Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178459 | 0.87 | CHRM2 (0.51) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL28741984 | 0.87 | OPRM1 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL22966099 | 0.86 | OPRM1 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL3302635 | 0.82 | OPRM1 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL9884888 | 0.82 | OPRM1 (0.52) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL12347237 | 0.81 | OPRM1 (0.51) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL1715453 | 0.81 | HRH3 (0.50) | OPRM1CHRM2CHRM3 | |
| Hydrochloric Acid SCHEMBL8479224 | 0.81 | OPRM1 (0.51) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL7499304 | 0.80 | CCR5 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL34474746 | 0.80 | CCR5 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | OPRM1 1475/4885SIGMAR1 1243/4885CHRM2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.